Overview

A Study of 5 Fluorouracil and the Anti-Tumor Activity of ADH300004 and 5 Fluorouracil in Subjects With Incurable Solid Tumors

Status:
Suspended

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

5 fluorouracil (5 FU), one of the most actively investigated anti-cancer drugs, is rapidly inactivated by the enzyme dihydropyrimidine dehydrogenase (DPD). ADH300004 blocks DPD. This study will test the safety and effects of oral ADH300004 14 hours prior to oral 5 FU in subjects with refractory solid tumors.

Phase:

Phase 1

Details

Lead Sponsor:

Adherex Technologies, Inc.

Treatments:

Eniluracil
Fluorouracil